Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/ nucleotide inhibitors
- 1 April 2009
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 15 (3), 401-412
- https://doi.org/10.3851/imp1541
Abstract
Background: To reduce the incidence of drug resistance and to maintain viral suppression, patients chronically infected with HBV might require combination therapy using two or more drugs with different resistance pro-files. We investigated the activity of clevudine (CLV) in combination with other nucleoside/nucleotide analogues to determine if these combinations were compatible in vitro. Methods: Using the HepAD38 cell line, which expresses wild-type HBV, and a real-time PCR assay, we tested the anti-HBV activity of CLV in combination with entecavir, lamivudine, adefovir, tenofovir and telbivudine (TBV). We evaluated the uptake and phosphorylation of CLV in the presence of TBV, using HepAD38 cells and primary hepatocytes to determine the effect of TBV on the phosphorylation of CLV and vice versa. Phosphorylation of TBV and CLV to their corresponding monophosphate by deoxycytidine kinase, thymidine kinase-1 and thymidine kinase-2, and the phosphorylation of TBV monophosphate and CLV monophosphate by thymidylate kinase was evaluated and compared. Results: When CLV was combined with entecavir, lamivudine, adefovir or tenofovir, a synergistic antiviral effect was observed; however, the combination of CLV and TBV gave an antagonistic antiviral response. The results of in vitro metabolism and enzyme studies suggest that the antagonism observed with the CLV/TBV combination involves competition for uptake and phosphorylation. Conclusions: The results of our studies demonstrate that combination treatments can provide enhanced antiviral activity and, when used in conjunction with appropriate metabolic investigations, provide a rational basis for the design and development of combination regimens for treating chronic HBV infection.Keywords
This publication has 28 references indexed in Scilit:
- Identification of a putative human mitochondrial thymidine monophosphate kinase associated with monocytic/macrophage terminal differentiationGenes to Cells, 2008
- Human UMP-CMP Kinase 2, a Novel Nucleoside Monophosphate Kinase Localized in MitochondriaPublished by Elsevier BV ,2008
- Mitochondrial Thymidine Kinase and the Enzymatic Network Regulating Thymidine Triphosphate Pools in Cultured Human CellsJournal of Biological Chemistry, 2007
- Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppressionHepatology, 2007
- Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis BHepatology, 2007
- Mechanism of Activation of β- d -2′-Deoxy-2′-Fluoro-2′- C -Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA PolymeraseAntimicrobial Agents and Chemotherapy, 2007
- Mitochondrial deoxynucleotide pool sizes in mouse liver and evidence for a transport mechanism for thymidine monophosphateProceedings of the National Academy of Sciences of the United States of America, 2006
- Bromovinyl-deoxyuridine: A selective substrate for mitochondrial thymidine kinase in cell extractsBiochemical and Biophysical Research Communications, 2006
- Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection ModelAntimicrobial Agents and Chemotherapy, 2003
- Drug Combinations and Effect Parameters of Zidovudine, Stavudine, and Nevirapine in Standardized Drug-Sensitive and Resistant HIV Type 1 Strains*AIDS Research and Human Retroviruses, 1996